AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02942745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Betel Nut Cessation Booklet
Description: Participants will receive minimal intervention via a single booklet that contains all the information offered in the experimental group, minus the social support sessions. The participants will meet with study staff individually at a designated office in Guam or Saipan to receive the betel nut cessation booklet, complete three assessments (baseline, 22 days, 6 months), and provide saliva samples.
Study NCT02093013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated care program
Description: Integrated care program meant in effect, calling on the family medicine group (FMG) nurses to evaluate and support asthmatic patients. The FMG and asthma education centre (AEC) nurses received special training and followed a protocol based on the theoretical model and the Canadian asthma management recommendations then in force. The protocol had five main aspects: 1) asthma assessment, 2) self-management, 3) environment and lifestyle, 4) collaborative care plan, and 5) information sharing and follow-up.
Study NCT00841594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroglycerin 0.9 % (MXQ-503)
Description: MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
Study NCT00841594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin ointment 2%, USP
Description: MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
Study NCT04132362 — intervention group
Intervention type: BEHAVIORAL
Intervention: Personalised music listening
Description: People will be sequentially recruited to discover their favourite music playlist, monitor their emotional responses to specific songs and explore the impact of listening to the music, on their behavioural and psychological symptoms. This will be done through a one hour music listening session, to discover the top 10-20 songs they respond to. It will then be followed by multiple shorter music listening sessions, initiated by the dementia resident themselves or their carer, where they listen to their favourite songs during their day, before difficult moments of care or during visits with their families.
Study NCT04132362 — intervention group
Intervention type: BEHAVIORAL
Intervention: Using fMRI to investigate the effect of listening to personalised music evoking positive emotional response on brain activation
Description: 12 of the recruited participants, who have symptoms and signs of mild to moderate dementia will be invited to take part in this sub-study. Using an amended version of a previously employed fMRI paradigm, each study participant will be presented inside the MRI scanner with short 30 second epochs of music (identified as evoking a positive or neutral emotional response) in a block design. Each 30 second epoch of music will be followed by a 16 second period when participants will be asked to rate subjective changes in their affective state using a computerised visual analogue scale. Epochs of positive emotional stimuli will alternate with epochs of neutral emotional stimuli in a counterbalanced order of presentation in 2 runs of 10 epochs each (5 positive and 5 neutral in each run).
Study NCT04132362 — intervention group
Intervention type: BEHAVIORAL
Intervention: Personalised music listening in the community
Description: 1000 families affected by dementia will be invited to use our WebApp to create a personalised playlist for their loved one with dementia and share their perceptions of how the music has affected the well-being of their loved one.
Study NCT02671136 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hyperbaric Oxygen therapy
Study NCT02671136 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Wound Therapies
Study NCT02336490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discharge Medication Delivery Service
Description: hospital-owned outpatient pharmacy fills and delivers discharge medications to patients in their rooms prior to discharge
Study NCT01142102 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: A radical dose of radiotherapy to be delivered to the entire bladder volume: 64Gy in 32 fractions over 6 weeks and 2 treatment days.~* Conventional plan is used to deliver treatment for fractions 1 to 7 using a standard planning approach and a CTV to PTV margin of 1.5cm.~* Adaptive plan is used to deliver treatment for fractions 8 through 32 using the same standard techniques as for fractions 1 to 7 but using one of three specific CTV volumes,namely: small, average or large. In all these cases the CTV to PTV margin is 0.7cm. Image guidance using a treatment unit based verification CT unit (Cone Beam CT or CT on Rails)based on soft tissue delineation is used to position the treatment fields and select the plan to best cover the CTV.
Study NCT04827784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local anaesthetic injection
Description: The head and neck of the condyle were detected by palpating the pretragal area. Then, the needle was inserted anterior to the junction of the tragus and the lobule. After 0.5 ml the solution was subcutaneously infiltrated, the needle was protruded until it touched the neck of the condyle. Aspiration was performed to avoid intravenous injections, and the remaining solution was injected thereafter.
Study NCT00996944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole immediate release (IR)
Description: Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime. The maximum available dose is 3 mg/day. For all subjects completing short-term period and entering the long-term treatment period, the open-label treatment will be started from IR 0.25 mg/ day regardless of dose levels during short-term period. The dose will be upward titrated from 0.25 mg/day to 0.5 mg/day and after that in increments of 0.5 mg/day until sufficient efficacy is obtained (targeting much improved or very much improved in the CGI-I) without safety/tolerability problem.
Study NCT00996944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime.
Study NCT01310894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOOKAD® Soluble
Description: TOOKAD® Soluble-VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
Study NCT03910907 — intervention group
Intervention type: DRUG
Intervention: Comparison of two standard of care regimens
Description: Treatment according to results of laboratory detection of resistance markers
Study NCT02027142 — intervention group
Intervention type: OTHER
Intervention: Pittsburgh Sleep Quality Index.
Description: Pittsburgh Sleep Quality Index is an effective instrument used to measure the quality and patterns of sleep of patients. It allows evaluating poor from good sleep by assessing seven domains. A total score ≤ 5 indicated good sleep quality while a total score > 5 was indicated poor sleep quality.
Study NCT02027142 — intervention group
Intervention type: OTHER
Intervention: Epworth sleepiness scale.
Description: Epworth sleepiness scale is an 8-item questionnaire developed to measure average daytime sleepiness. A total score ≥ 10 indicates excessive daytime sleepiness.
Study NCT02027142 — intervention group
Intervention type: OTHER
Intervention: Insomnia Severity Index.
Description: Insomnia Severity Index is a 7-item questionnaire developed to measure insomnia. A total score between 0 and 7 correspond to not clinically significant insomnia, between 8 and 14 to subthreshold insomnia, between 15 and 21 to clinical insomnia (moderate), between 22 and 28 to clinical insomnia (severe).
Study NCT02027142 — intervention group
Intervention type: OTHER
Intervention: The Endometriosis Health Profile.
Description: The Endometriosis Health Profile is a patient generated instrument that evaluates disease-specific health-related quality of life in patients with endometriosis. The questionnaire is administrable to all patients with endometriosis and it consists in 30 items divided in 5 domains (pain, control and powerlessness, emotional well-being, social support and self-image). Each scale for each domain is comprised between 0 (indicating the best health status) and 100 (indicating the worst health status).
Study NCT02806297 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early cholecystectomy with IOC
Description: The intervention will be laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) on admission within 24 hours of presentation regardless of whether pain or tenderness are present or laboratory values are elevated.
Study NCT02806297 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late cholecystectomy with IOC
Description: The control will be laparoscopic cholecystectomy with IOC once the patient has met the following criteria: (a) a score of less than 2 on the Visual Analogue Pain Scale, (b) no tenderness on physical exam, and (c) decreased lipase to either less than half of the peak value or within normal range (73-393 U/L).
Study NCT04522089 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimrSC-2f
Description: AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune). Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified. AdimrSC-2f is formulated in the different dosages of Spike (S) protein without/with aluminum content as adjuvant.
Study NCT03539055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate Oral Capsule
Description: Oral use of Dabigatran etexilate for 90 days BID per product labeling for dosage to reduce incidence of device related thrombus after implantation of a Watchman LAA device.
Study NCT01508871 — intervention group
Intervention type: OTHER
Intervention: Observational study, no intervention
Description: No intervention
Study NCT02424253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZPL-3893787
Description: ZPL-3893787
Study NCT02424253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched Placebo
Study NCT01455688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: early HAART
Description: Initiation of HAART within 5 days of ICU admission
Study NCT01455688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Late HAART
Description: Initiation of HAART after ICU discharge
Study NCT03889977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: 2 major muscle groups (lower extremity, chest)
Study NCT02243215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to a portable trainer for laparoscopic skills
Description: Participants will have a portable trainer available to allow training at their convenience, and will be able practice on-site at Center of Clinical Education and at their local hospital.
Study NCT01886365 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Space GlucoseControl System, B. Braun, Melsungen, Germany
Description: Computerized algorithmic application of insulin
Study NCT01886365 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional therapy with a fixed insulin dosing scheme
Description: Routine care
Study NCT00935480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isentress®
Description: P.O, 1 tablet containing 400 mg every 12 hours
Study NCT00935480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celsentri®
Description: p.o.: 1 tablet containing 150 mg morning and evening (due to combination with PI/r) or containing 300 mg if fosamprenavir/r is used as the PI (MA)
Study NCT00949546 — intervention group
Intervention type: DRUG
Intervention: etanercept
Description: etanercept 50 mg sc twice weekly
Study NCT01136655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80/2.25 μg Symbicort pMDI
Description: inhalation
Study NCT01136655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80/4.5 μg Symbicort pMDI
Description: inhalation
Study NCT01136655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foradil Aerolizer 12 μg
Description: inhalation
Study NCT01136655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 40 μg budesonide HFA pMDI
Description: inhalation
Study NCT01136655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 μg budesonide HFA pMDI
Description: inhalation
Study NCT01136655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 μg budesonide HFA pMDI
Description: inhalation
Study NCT01136655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo HFA pMDI
Description: inhalation
Study NCT01136655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo HFA pMDI
Description: inhalation
Study NCT01617980 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multimodal hypoxia imaging
Description: Patients with inoperable, stage III non-small cell lung cancer receive serial 18F-FMISO dPET-CT and functional MRI investigations prior, during and post radiation treatment
Study NCT02278900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication aids
Description: Question Prompt list Audiofile
Study NCT02937818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab and Tremelimumab
Description: Durvalumab + tremelimumab via intravenous (IV) infusion every 4 weeks (q4w), starting on Week 0, for up to a total of 4 months (4 cycles) followed by durvalumab monotherapy via IV infusion q4w, starting on Week 16 until PD, or for other discontinuation criteria.
Study NCT02937818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775 and carboplatin (CBPT)
Description: AZD1775 twice daily (oral) for 2.5 days from Day 1 + CBDP area under the curve 5 (Day1) (IV); every 3 weeks.
Study NCT02937818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738 and olaparib
Description: AZD6738 once a day (oral) for 7 days from Day 1 + olaparib twice a day(oral) for 28 days from Day 1, every 4 weeks
Study NCT00768521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine tartrate
Description: Part I: tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose tolterodine tartrate 4 mg capsule
Study NCT00768521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo to tolterodine tartrate
Description: Part I: placebo to tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: placebo to tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose placebo to tolterodine tartrate 4 mg capsule
Study NCT02970890 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portable Pain Away™
Description: Portable Pain Away™ device (manufactured by Multi Radiance Medical, Solon - OH, USA) - placebo or active phototherapy
Study NCT02970890 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Portable Pain Away™
Description: Portable Pain Away™ device (manufactured by Multi Radiance Medical, Solon - OH, USA) - placebo or active phototherapy
Study NCT02756507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video-based transdiagnostic REBT
Description: The video-based transdiagnostic REBT consists of 6 sessions delivered in a group format.
Study NCT02756507 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Wait list
Description: Delayed intervention
Study NCT00193063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab
Study NCT00193063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine
Study NCT02881632 — intervention group
Intervention type: DEVICE
Intervention: Structured Light Plethysmography (SLP) - Pneumscan
Description: Both healthy infants and bronchiolitis infants will have their chest movements monitored using Structured Light Plethysmography (SLP) performed by a device (Thora-3 Di) using a projector and two cameras. A light pattern of black and white squares is projected on the child's chest and the cameras record how the shape of this pattern changes with breathing. A computer converts this information to show how the child's chest moves during breathing.
Study NCT02573363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given per standard of care
Study NCT02573363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given per standard of care
Study NCT02573363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO
Study NCT02228590 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: APL-130277
Description: Apomorphine Hydrochloride, Sublingual Thin Film
Study NCT04012047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levcromakalim
Description: To investigate the role of levcromakalim compared with placebo in migraine with aura patients
Study NCT04012047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: To investigate the role of levcromakalim compared with placebo in migraine with aura patients
Study NCT02062788 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution
Description: Preoperative day #1: able to drink Oral rehydration solution (ORS) freely On day of Surgery: Allowed administration until 2hrs prior to surgery. 8AM patients(the first patients to undergo surgery of the day) are recommended to administer ORS at 5:30AM
Study NCT00604604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support
Description: Mothers allocated to the peer support group had access to all of the standard community postpartum services in addition to having received telephone-based support from a peer volunteer (a mother who has previously experienced, and recovered from, postpartum depression and has participated in a 4-hour training session). Telephone contact with a new mother was initiated within 48 to 72 hours of trial enrolment and then as frequently as the dyad deemed necessary; a minimum of four contacts were required.
Study NCT03519763 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound
Description: All the patients will have a transvaginal ultrasound evaluation during the first visit to the clinic to evaluate the presence or not of isthmocele.
Study NCT02503228 — intervention group
Intervention type: PROCEDURE
Intervention: Standard of care osteochondral and or meniscal allograft transplantation
Description: Standard of care osteochondral and or meniscal allograft transplantation
Study NCT02268903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretics : Furosemide
Description: Furosemide 80mg in one single direct intra venous injection
Study NCT02268903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in one single direct intra venous injection
Study NCT01168648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga as stress management
Description: Yoga specially designed to reduce stress is practiced for approximately 30 minutes at least three times a week for three months, once in a group session led by a trained yoga instructor and twice or more at home. The yoga techniques used are physical postures or movements, meditation and breathing exercises. Every time they do the techniques, participants fill in a form detailing how they feel before and after and providing information on the experience of doing the exercises.
Study NCT01168648 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Yoga as stress management
Description: Yoga specially designed to reduce stress is practiced for approximately 30 minutes at least three times a week for three months, once in a group session led by a trained yoga instructor and twice or more at home. The yoga techniques used are physical postures or movements, meditation and breathing exercises. Every time they do the techniques, participants fill in a form detailing how they feel before and after and providing information on the experience of doing the exercises.
Study NCT01168648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rest without using any relaxation technique
Description: The participants rest at home at least 30 minutes, at least three times a week for three months and without using any relaxation technique
Study NCT01579448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shanchol™, oral cholera vaccine
Description: This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.~Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension.